"Cannabinoids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds having the cannabinoid structure. They were originally extracted from Cannabis sativa L. The most pharmacologically active constituents are TETRAHYDROCANNABINOL; CANNABINOL; and CANNABIDIOL.
| Descriptor ID |
D002186
|
| MeSH Number(s) |
D02.455.849.090
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cannabinoids".
Below are MeSH descriptors whose meaning is more specific than "Cannabinoids".
This graph shows the total number of publications written about "Cannabinoids" by people in this website by year, and whether "Cannabinoids" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 4 | 3 | 7 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 0 | 2 | 2 |
| 2015 | 2 | 3 | 5 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 1 | 4 |
| 2018 | 4 | 0 | 4 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cannabinoids" by people in Profiles.
-
Hodebourg R, Meyerink ME, Crow AD, Reichel CM, Kalivas PW, Garcia-Keller C. Cannabinoid use is enhanced by stress and changes conditioned stress responses. Neuropsychopharmacology. 2022 04; 47(5):1037-1045.
-
Borodovsky JT, Sofis MJ, Sherman BJ, Gray KM, Budney AJ. Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints. Psychol Addict Behav. 2022 Aug; 36(5):515-525.
-
Holloman BL, Nagarkatti M, Nagarkatti P. Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases. Int J Mol Sci. 2021 Jul 07; 22(14).
-
Andersen HK, Walsh KB. Molecular signaling of synthetic cannabinoids: Comparison of CB1 receptor and TRPV1 channel activation. Eur J Pharmacol. 2021 Sep 15; 907:174301.
-
Walsh KB, Andersen HK. Molecular Pharmacology of Synthetic Cannabinoids: Delineating CB1 Receptor-Mediated Cell Signaling. Int J Mol Sci. 2020 Aug 25; 21(17).
-
Apul OG, Rowles LS, Khalid A, Karanfil T, Richardson SD, Saleh NB. Transformation potential of cannabinoids during their passage through engineered water treatment systems: A perspective. Environ Int. 2020 04; 137:105586.
-
Neuhofer D, Spencer SM, Chioma VC, Beloate LN, Schwartz D, Kalivas PW. The loss of NMDAR-dependent LTD following cannabinoid self-administration is restored by positive allosteric modulation of CB1 receptors. Addict Biol. 2020 11; 25(6):e12843.
-
Al-Ghezi ZZ, Busbee PB, Alghetaa H, Nagarkatti PS, Nagarkatti M. Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome. Brain Behav Immun. 2019 11; 82:25-35.
-
Dong C, Chen J, Harrington A, Vinod KY, Hegde ML, Hegde VL. Cannabinoid exposure during pregnancy and its impact on immune function. Cell Mol Life Sci. 2019 Feb; 76(4):729-743.
-
Pandey P, Roy KK, Liu H, Ma G, Pettaway S, Alsharif WF, Gadepalli RS, Rimoldi JM, McCurdy CR, Cutler SJ, Doerksen RJ. Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists. Molecules. 2018 Oct 13; 23(10).